Clinical trials: Non-alcoholic Steatohepatitis (NASH)
Non-Alcoholic Fatty Liver Disease
Macrophage-mediated Inflammation in White Adipose Tissue and Non-alcoholic Fatty Liver Disease.
Non-alcoholic fatty liver disease (NAFLD) is present in one third of the population and due to its potential to cause irreversible liver damage and liver cancer, it is a significant health burden.
- Trial name
- NCT04059068
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Imperial College London
Obesity, NAFLD
Low-Calorie Diet in People With Prediabetes/Metabolic Syndrome
Significant weight reduction, achieved by low-calorie diet (LCD), will mobilise ectopic fat (visceral and particularly liver fat), improving insulin sensitivity and other metabolic syndrome components, with secondary beneficial…
- Conditions
- Obesity, NAFLD, Fatty Liver, Pre Diabetes
- Trial name
- CALIBRATE (NCT04786418)
- Testing
- Standard of care, Low-calorie diet
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
The investigators use machine learning capabilities on massive electronic health records for the purpose of developing a model that prioritizes individuals at high risk of progressing to liver cirrhosis, and validating it with…
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease, Fibrosis, Liver, Cirrhosis, Liver
- Trial name
- NCT05218538
- Testing
- Fibroscan (non interventional)
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- HaEmek Medical Center, Israel
Steatohepatitis
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
This is a controlled study to determine the effectiveness and safety of ethyl icosapentate (EPA-E) in the treatment of adult patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT01154985
- Testing
- EPA-E 300 mg capsule
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 243 people
- Sponsor
- Mochida Pharmaceutical Company, Ltd.
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
- Trial name
- NCT05728697
- Testing
- Endoscopic ultrasound shear wave elastography
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Brigham and Women's Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
This study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty…
- Trial name
- NCT07527910
- Testing
- ALN-PNP, Tirzepatide
- Where
- 9 sites in United States
- Volunteers
- 204 people
- Sponsor
- Regeneron Pharmaceuticals
Nonalcoholic Fatty Liver
Vitamin D Replacement in Nonalcoholic Fatty Liver Disease
Vitamin D deficiency is very common in patients with fatty liver disease as evidenced by our observations in the Metabolic Liver Clinic and that reported by others.
- Trial name
- NCT03084328
- Testing
- Vitamind D
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- The Cleveland Clinic
Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
The goal of this observational study is to investigate the associations between a novel inflammatory marker, high sensitivity C-reactiveprotein to albumin ratio (hsCAR), and steatosis and fibrosis of metabolic…
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
- Trial name
- NCT05974904
- Testing
- high-sensitivity C-reactive protein to albumin ratio
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- Chongqing Medical University
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study…
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05560607
- Testing
- AZD7503 Intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Nonalcoholic Fatty Liver
Effect of Adding TENS to Mediterranean Diet on Appetite and Liver Enzymes in Nonalcoholic Fatty Liver Patients
This study aims to identify the effect of adding TENS to the Mediterranean diet on appetite and liver enzymes in Nonalcoholic fatty liver patients.
- Trial name
- NCT07200934
- Testing
- Transcutaneous electrical stimulation (TENS), Mediterranean Diet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Nonalcoholic Fatty Liver
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
- Trial name
- NCT03763877
- Testing
- PXL770
- Where
- 15 sites in United States
- Volunteers
- 121 people
- Sponsor
- Poxel SA
Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Trial name
- NCT03884075
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease, Obesity
Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).
Nonalcoholic steatohepatitis is a growing public health problem affecting over 5% of the population. These patients are at increased risk of cardiovascular and liver-related death and have higher rates of malignancy.
- Trial name
- NASH-APOLLO (NCT03426111)
- Testing
- Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA), Lifestyle modification
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Puerta de Hierro University Hospital
NAFLD, Insulin Resistance
Determination of Insulin-stimulated Hepatic Glucose Uptake by PET-CT Measurements
In the absence of excessive alcohol consumption, increased levels of fat in the liver (>5%) are diagnosed as non-alcoholic fatty liver (NAFL).
- Conditions
- NAFLD, Insulin Resistance, Overweight and Obesity
- Trial name
- ISGU (NCT04938544)
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Esophageal Varices, Non-alcoholic Fatty Liver
Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
Non-alcoholic fatty liver disease (NAFLD) is defined as accumulation of fat in the liver which is not related to either alcohol excess or other causes such viral infection, immune-mediated, or medication related which can lead to…
- Conditions
- Esophageal Varices, Non-alcoholic Fatty Liver, Compensated Cirrhosis
- Trial name
- NCT05485714
- Testing
- Reviewing records retrospectively of patients undergoing screening endoscopy
- Where
- United Arab Emirates
- Volunteers
- 73 people
- Sponsor
- United Arab Emirates University
Chronic Hepatitis b, NAFLD
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.
- Conditions
- Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver
- Trial name
- NCT05147090
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Fatty Liver
Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity
Were included 40 patients with NAFLD followed at the Ambulatory of Non-alcoholic Fatty Liver Disease , Discipline of Clinical Gastroenterology, Clinic Hospital of the Medical School of the University of Sao Paulo (HC-FMUSP).
- Trial name
- NCT02427087
- Testing
- Continuous Aerobic Training twice, Healthy Diet
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Non-alcoholic Steatohepatitis (NASH)
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.
- Trial name
- NCT02316717
- Testing
- IMM-124E
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 133 people
- Sponsor
- Immuron Ltd.
NASH With Fibrosis, MASH With Fibrosis
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3).
- Trial name
- NCT06215716
- Testing
- Efruxifermin
- Where
- 359 sites in United States, Argentina and 16 more
- Volunteers
- 1,650 people
- Sponsor
- Akero Therapeutics, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.